SCHEMBL2391520

SCHEMBL2391520

O=C(O)c1ccc(C(=O)Nc2cc3c4c(c2)CCCCC4CCCC3)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.45
KDM4E B2RXH2 3/20 0.45
NPC1 O15118 2/20 0.45
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.44
GLA P06280 1/20 0.44
HTT P42858 1/20 0.44
HIF1A Q16665 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
P4HTM Q9NXG6 8/20 0.43
HCAR3 P49019 2/20 0.43
TP53 P04637 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
P4HA1 P13674 1/20 0.42
MIF P14174 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2396462 0.96 RAB9A (0.46) RAB9AKDM4ENPC1ALDH1A1SMN1; SMN2
SCHEMBL2393099 0.88 P4HTM (0.55) RAB9AKDM4ENPC1ALDH1A1SMN1; SMN2
SCHEMBL2394634 0.88 MAPK1 (0.48) RAB9AKDM4ENPC1ALDH1A1SMN1; SMN2
SCHEMBL2394945 0.85 RAB9A (0.51) RAB9ANPC1ALDH1A1SMN1; SMN2MAPT
SCHEMBL2394759 0.84 MAPK1 (0.49) RAB9AKDM4ENPC1ALDH1A1SMN1; SMN2
SCHEMBL2396270 0.81 HCAR3 (0.56) RAB9ANPC1HCAR3
SCHEMBL2394947 0.81 RAB9A (0.52) RAB9ANPC1ALDH1A1SMN1; SMN2MAPT
SCHEMBL2392565 0.81 MAPK1 (0.48) RAB9AKDM4ENPC1ALDH1A1SMN1; SMN2
SCHEMBL2393053 0.79 MEN1 (0.52) RAB9ANPC1ALDH1A1SMN1; SMN2MAPT
SCHEMBL2398637 0.79 P4HTM (0.59) RAB9AKDM4ENPC1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
EP-2189443-A1 TRICYCLIC AMIDE COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG RAB9A 1612/4885KDM4E 3386/4885NPC1 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.